Cell & Gene Therapy CDMOs — Ranked by Signal Score · 2026
141
CDMOs tracked
106
Fully scored
31
With FDA records
107
FDA inspections
323
EMA/MHRA GMP certs
8
Warning letters
On CDMO Signal's composite Signal Score, Bristol Myers Squibb (CGT Mfg), Novartis, and City of Hope (T Cell Manufacturing) lead the cell and gene therapy CDMO rankings — an aggregation across cell therapy manufacturers (CAR-T, TCR, NK, stem cell) and viral vector manufacturers (AAV, lentiviral, adenoviral). The Signal Score is a 0–100 composite of four weighted pillars — Quality Compliance (35%), Operations (25%), Financial Stability (20%), and Capacity Intelligence (20%) — built from FDA inspection history, EMA/MHRA GMP certificates, ClinicalTrials.gov sponsor footprint, and monitored capacity signals. Ex vivo cell therapy programs typically pair a lentiviral vector supplier with a cell processing CDMO; sponsors running combined scope often prefer integrated CDMOs to reduce tech transfer risk. For platform-filtered rankings see the dedicated cell therapy, AAV, and lentiviral pages. Full methodology at cdmosignal.com/methodology.
Cell and gene therapy manufacturing spans two adjacent product classes: living cell products (CAR-T, TCR, NK, stem cell therapies) and the viral vectors used to genetically modify them (AAV, lentiviral, adenoviral). The two are tightly coupled in ex vivo cell engineering — a lentiviral vector CDMO supplies the vector that a cell therapy CDMO uses to modify patient T cells for CAR-T. Sponsors running integrated programs benefit from CDMOs covering both, and the ranking below aggregates that combined view.
For platform-specific rankings, use the dedicated pages: <a href="/modality/cell-therapy">Cell Therapy CDMOs</a>, <a href="/modality/aav">AAV CDMOs</a>, <a href="/modality/lentiviral">Lentiviral Vector CDMOs</a>, <a href="/modality/adenoviral">Adenoviral Vector CDMOs</a>, <a href="/modality/gene-therapy">Gene Therapy CDMOs</a> (vectors only, no cell processing).
FDA inspection outcomes across these CDMOs: 48 NAI (no action), 54 VAI (voluntary action), 5 OAI (official action). Leading inspection & GMP sites: United States (89), UNITED KINGDOM (68), Austria (51), Germany (40), Denmark (35).
Last updated 2026-08-22. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
| # | CDMO | Signal Score | Quality | FDA · GMP | Capacity | Programs |
|---|---|---|---|---|---|---|
| 1 |
BMS
Bristol Myers Squibb (CGT Mfg)
Bothell, WA · Warren, NJ
|
90.8 | 97.0 | 6 insp · 2 GMP | — | 583 programs |
| 2 |
Novartis
Basel, Switzerland
|
88.3 | 90.9 | 15 insp · 62 GMP | — | 135 programs |
| 3 |
COH
City of Hope (T Cell Manufacturing)
Duarte, CA
|
83.8 | 96.8 | 3 insp · 0 GMP | — | 211 programs |
| 4 |
TF
Thermo Fisher Scientific
Plainville, MA · Alachua, FL · Cambridge, MA
|
83.1 | 97.9 | 6 insp · 10 GMP | Available | 2 programs |
| 5 |
MK
Merck KGaA / MilliporeSigma (CDMO)
Darmstadt, DE · St. Louis, MO
|
81.8 | 98.6 | 2 insp · 2 GMP | — | 22 programs |
| 6 |
AG
AGC Biologics
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
|
80.6 | 99.9 | 2 insp · 23 GMP | Available | 2 programs |
| 7 |
TK
Takeda
Boston, MA · Zurich, CH
|
80.5 | 99.3 | 4 insp · 18 GMP | — | 100 programs |
| 8 |
BY
Bayer (Cell Therapy Mfg)
Berkeley, CA
|
79.2 | 86.9 | 8 insp · 17 GMP | — | 126 programs |
| 9 |
CS
Cedars-Sinai Biomanufacturing
Los Angeles, CA
|
78.9 | 100.0 | 1 insp · 0 GMP | — | 34 programs |
| 10 |
Lonza
Basel, Switzerland
|
78.2 | 95.1 | 2 insp · 8 GMP | — | 1 programs |
| 11 |
OX
Oxford Biomedica
Oxford, United Kingdom
|
77.1 | 100.0 | 0 insp · 13 GMP | Available | 7 programs |
| 12 |
CI
Cincinnati Children's Vector Production Facility
Cincinnati, OH
|
75.2 | 100.0 | 1 insp · 0 GMP | — | 1 programs |
| 13 |
MB
Miltenyi Biotec
Bergisch Gladbach, Germany
|
74.6 | 100.0 | 0 insp · 2 GMP | — | 8 programs |
| 14 |
NR
National Resilience
San Diego, CA · Boston, MA · RTP, NC · Philadelphia, PA
|
73.4 | 97.7 | 1 insp · 0 GMP | Available | 9 programs |
| 15 |
RT
ReiThera
Rome, IT
|
71.1 | 100.0 | 0 insp · 4 GMP | — | 1 programs |
| 16 |
CR
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
|
91.7 | 98.7 | 8 insp · 11 GMP | Limited | 0 programs |
| 17 |
RP
ReciBioPharm
Keele, UK · Sodertalje, SE
|
88.0 | 100.0 | 0 insp · 3 GMP | — | 0 programs |
| 18 |
PB
Pharmaron Biologics
San Diego, CA · Shaoxing, China, Liverpool, UK, Ningbo China
|
86.9 | 100.0 | 3 insp · 0 GMP | Available | 0 programs |
| 19 |
AJ
Ajinomoto Bio-Pharma Services
San Diego, CA · Osaka, JP
|
85.6 | 100.0 | 0 insp · 1 GMP | — | 0 programs |
| 20 |
LB
Lotte Biologics
Incheon, KR · Syracuse, NY
|
83.7 | 100.0 | 1 insp · 0 GMP | — | 0 programs |
| 21 |
WB2
WuXi Biologics
Shanghai, CN · Wuxi, CN
|
83.7 | 100.0 | 0 insp · 4 GMP | — | 0 programs |
| 22 |
KB
KBI Biopharma
Durham, NC · Boulder, CO
|
83.5 | 100.0 | 1 insp · 1 GMP | Limited | 0 programs |
| 23 |
FD
FUJIFILM Diosynth Biotechnologies
Research Triangle, NC · Holly Springs, NC · Hillerod, DK
|
83.5 | 100.0 | 0 insp · 23 GMP | 0 programs | |
| 24 |
MN
Minaris Advanced Therapies
Philadelphia, PA · Allendale, NJ · Munich, DE · Yokohama, JP
|
83.5 | 100.0 | 1 insp · 6 GMP | Limited | 0 programs |
| 25 |
SC
SCTbio
Prague, Czech Republic
|
81.6 | 100.0 | 0 insp · 5 GMP | — | 0 programs |
| 26 |
EF
Eurofins CDMO
Planegg, DE · San Diego, CA
|
81.6 | 100.0 | 5 insp · 0 GMP | — | 0 programs |
| 27 |
DH
Danaher (CGT Portfolio)
Washington, DC
|
81.5 | — | — | — | 0 programs |
| 28 |
BR
BioReliance (Merck)
Glasgow, UK · Rockville, MD
|
81.0 | 98.8 | 4 insp · 8 GMP | — | 0 programs |
| 29 |
NW
Northway Biotech
Vilnius, LT; Waltham (MA), USA
|
80.8 | 100.0 | 0 insp · 8 GMP | Available | 0 programs |
| 30 |
CF
CELLforCURE (SEQENS)
Les Ulis, FR
|
80.3 | 100.0 | 0 insp · 4 GMP | — | 0 programs |
| 31 |
RC
RoslinCT
Edinburgh, UK · Hopkinton, MA
|
80.2 | 98.8 | 1 insp · 1 GMP | Available | 0 programs |
| 32 |
SG
Syngene International
Bengaluru, India
|
79.7 | 95.9 | 2 insp · 0 GMP | — | 0 programs |
| 33 |
OB
OmniaBio
Hamilton, ON
|
79.5 | 100.0 | 0 insp · 2 GMP | — | 0 programs |
| 34 |
GS
GenScript ProBio
Piscataway, NJ · Nanjing, CN
|
79.5 | 100.0 | — | Constrained | 0 programs |
| 35 |
SK
SK pharmteco
Dublin, Ireland. Rancho Cordova, CA. King of Prussia, PA. Houston, TX. Korea. France.
|
79.5 | 100.0 | — | Available | 0 programs |
| 36 |
PG
ProBioGen
Berlin, DE
|
78.9 | 100.0 | 0 insp · 2 GMP | — | 0 programs |
| 37 |
XP
eXmoor Pharma
Bristol, United Kingdom
|
78.7 | 100.0 | 0 insp · 1 GMP | — | 0 programs |
| 38 |
BB
bluebird bio Manufacturing
Durham, NC
|
78.5 | — | — | — | 0 programs |
| 39 |
AA
Ascend Advanced Therapies
London, United Kingdom
|
78.1 | 100.0 | 0 insp · 1 GMP | — | 0 programs |
| 40 |
NG
NecstGen
Leiden, NL
|
78.1 | 100.0 | 0 insp · 1 GMP | — | 0 programs |
| 41 |
ET
Exothera
Jumet, BE
|
78.1 | 100.0 | 0 insp · 4 GMP | — | 0 programs |
| 42 |
OR
Ori Biotech
London, UK
|
78.1 | 100.0 | 0 insp · 1 GMP | — | 0 programs |
| 43 |
CC
CCRM
Toronto, ON, Canada
|
78.1 | 100.0 | 5 insp · 0 GMP | — | 0 programs |
| 44 |
CE
Celonic
Basel, Switzerland
|
78.1 | 100.0 | 0 insp · 1 GMP | — | 0 programs |
| 45 |
AD
Advent Bioservices
London, United Kingdom
|
78.1 | 100.0 | 0 insp · 2 GMP | — | 0 programs |
| 46 |
GP
Green Phoenix Labs
San Diego, CA
|
78.1 | 100.0 | 0 insp · 1 GMP | — | 0 programs |
| 47 |
BV
Biovian
Turku, Finland
|
78.0 | 99.7 | 1 insp · 4 GMP | — | 0 programs |
| 48 |
AG2
August Bioservices
San Carlos, CA
|
77.4 | 98.5 | 1 insp · 0 GMP | — | 0 programs |
| 49 |
BC
Biocon Biologics
Bangalore, India
|
77.1 | 96.1 | 4 insp · 2 GMP | — | 0 programs |
| 50 |
VG
Viralgen Vector Core
San Sebastián, Spain
|
76.8 | 100.0 | 0 insp · 4 GMP | Available | 0 programs |
| 51 |
SY
Symbiosis Pharmaceutical Services
Stirling, United Kingdom
|
76.8 | 100.0 | 1 insp · 9 GMP | — | 0 programs |
| 52 |
IP
Intas Pharmaceuticals
Ahmedabad, India
|
76.8 | 100.0 | 0 insp · 5 GMP | — | 0 programs |
| 53 |
CY
Cell-Easy
Toulouse, FR
|
76.8 | 100.0 | 0 insp · 2 GMP | — | 0 programs |
| 54 |
CN
Cellin Technologies
Luxembourg, LU
|
76.8 | 100.0 | 0 insp · 1 GMP | — | 0 programs |
| 55 |
HH
HiTech Health
London, United Kingdom
|
76.8 | 100.0 | 0 insp · 9 GMP | — | 0 programs |
| 56 |
Catalent
Bagsværd, Denmark (operating under Novo Holdings; legacy US operations headquartered in Somerset, NJ)
|
76.5 | 79.3 | 12 insp · 35 GMP | — | 0 programs |
| 57 |
FH
Fred Hutch Cell Therapy Lab
Seattle, WA
|
76.4 | — | — | — | 453 programs |
| 58 |
CA
Catalent (Novo Holdings)
Harmans, MD · Gosselies, BE
|
75.1 | 79.3 | 1 insp · 0 GMP | Available | 0 programs |
| 59 |
CG
Cytiva (Mfg Services)
Marlborough, MA · Uppsala, SE
|
74.0 | — | — | — | 0 programs |
| 60 |
LZ
Lonza Biologics
Houston, TX · Portsmouth, NH · Geleen, NL · Basel, CH
|
72.8 | 95.1 | 1 insp · 0 GMP | Limited | 0 programs |
| 61 |
VE
Vigene Biosciences
Rockville, MD
|
72.5 | — | — | — | 0 programs |
| 62 |
EM
Emergent BioSolutions (CGT)
Baltimore, MD
|
71.0 | — | — | — | 4 programs |
| 63 |
IO
Iovance Biotherapeutics (Mfg)
Philadelphia, PA
|
70.8 | — | — | — | 31 programs |
| 64 |
GZ
Genezen
Indianapolis, IN · Lexington, MA
|
70.7 | 84.1 | 3 insp · 0 GMP | Available | 0 programs |
| 65 |
IU
Indiana University Vector Production Facility
Indianapolis, IN
|
66.2 | — | — | — | 49 programs |
| 66 |
GenScript
Piscataway, NJ (US HQ); Nanjing, China (primary operations)
|
65.5 | — | — | — | 0 programs |
| 67 |
AN
Andelyn Biosciences
Columbus, OH
|
63.0 | — | — | Available | 0 programs |
| 68 |
CT
CTMC
Houston, TX
|
63.0 | — | — | — | 0 programs |
| 69 |
UM
MassBiologics
Boston, MA
|
63.0 | — | 1 insp · 0 GMP | — | 0 programs |
| 70 |
RA
Recipharm Advanced Bio
Stockholm, Sweden (US operations: Watertown, MA; EU/global ATMP division of Recipharm AB)
|
63.0 | — | — | — | 0 programs |
| 71 |
HG
Hitachi Global Life Solutions (CGT)
Yokohama, Japan
|
63.0 | — | — | — | 0 programs |
| 72 |
SM
Sumitomo Chemical Advanced Medical
Tokyo, JP
|
63.0 | — | — | — | 0 programs |
| 73 |
EA
Esco Aster
Singapore, SG
|
63.0 | — | — | — | 0 programs |
| 74 |
FB
Forge Biologics
Columbus, OH
|
62.7 | — | — | 3 programs | |
| 75 |
MX
MaxCyte
Gaithersburg, MD
|
62.0 | — | — | — | 0 programs |
| 76 |
CL
Cellares
South San Francisco, CA
|
61.5 | — | — | Available | 0 programs |
| 77 |
MS
Made Scientific
Princeton, NJ
|
61.5 | — | — | — | 0 programs |
| 78 |
GF
GeneFab
Alameda, CA and South San Francisco
|
61.5 | — | — | Available | 0 programs |
| 79 |
Minaris (WuXi Advanced Therapies)
Philadelphia, PA / Yokohama, Japan
|
60.5 | — | — | — | 0 programs |
| 80 |
KC
Kincell Bio
Research Triangle Park, NC
|
60.5 | — | — | — | 0 programs |
| 81 |
UB
uBriGene Biosciences
Shanghai, CN · Boston, MA
|
60.5 | — | — | — | 0 programs |
| 82 |
AP
Applied StemCell
Milpitas, CA
|
60.5 | — | — | — | 0 programs |
| 83 |
CoJourney Inc.
Horsham, PA (US HQ); Hangzhou, China (primary GMP manufacturing)
|
60.0 | — | — | Limited | 0 programs |
| 84 |
AB
Asklepios BioPharmaceutical (AskBio)
Research Triangle, NC · San Sebastian, ES
|
59.7 | — | — | — | 10 programs |
| 85 |
TR
Takara Bio
Kusatsu, Shiga Prefecture, Japan
|
59.5 | — | — | — | 8 programs |
| 86 |
MA
Matica Biotechnology
College Station, TX
|
59.0 | — | — | Available | 0 programs |
| 87 |
VB
VintaBio
Cambridge, MA
|
59.0 | — | — | — | 0 programs |
| 88 |
WB
Waisman Biomanufacturing
Madison, WI
|
59.0 | — | — | — | 0 programs |
| 89 |
EB
ElevateBio BaseCamp
Waltham, MA
|
59.0 | — | — | — | 0 programs |
| 90 |
CP
Cell and Gene Therapy Catapult
Stevenage, United Kingdom
|
59.0 | — | — | — | 0 programs |
| 91 |
C3
C3i Center
Houston, TX
|
59.0 | — | — | — | 0 programs |
| 92 |
EX
Excellos
La Rochelle, France
|
59.0 | — | — | — | 0 programs |
| 93 |
CZ
Cellex Cell Professionals
Cologne, Germany
|
59.0 | — | — | — | 0 programs |
| 94 |
AS
Artis BioSolutions
Lake Nona, FL
|
59.0 | — | — | — | 0 programs |
| 95 |
VM
Vector BioMed
Cambridge, MA
|
59.0 | — | — | — | 0 programs |
| 96 |
AM
Anemocyte
Gerenzano, IT
|
59.0 | — | — | — | 0 programs |
| 97 |
HX
Helixmith
Seoul, KR
|
59.0 | — | — | — | 0 programs |
| 98 |
CTP
Cell Therapies Pty Ltd
Melbourne, Australia
|
59.0 | — | — | — | 0 programs |
| 99 |
SS
Singota Solutions
Bloomington, IN
|
59.0 | — | — | — | 0 programs |
| 100 |
DINAMIQS
Schlieren (Zurich), Switzerland
|
59.0 | — | — | Available | 0 programs |
| 101 |
PO
Poseida Therapeutics (CDMO)
San Diego, CA
|
58.7 | — | — | — | 6 programs |
| 102 |
TG
ThermoGenesis
Rancho Cordova, CA
|
57.8 | — | — | — | 1 programs |
| 103 |
CV
CEVEC Pharmaceuticals
Cologne, DE
|
56.5 | — | — | — | 0 programs |
| 104 |
CX
CellGenix
Freiburg, DE
|
56.5 | — | — | — | 0 programs |
| 105 |
GC
Green Cross Cell
Yongin, KR
|
56.5 | — | — | — | 0 programs |
| 106 |
CH
CHA Medical & Bio Group
Seongnam, KR
|
56.5 | — | — | — | 0 programs |
| — |
3P Biopharmaceuticals (now 3PBIOVIAN)
Pamplona-Noáin, Spain
|
Profiled | — | — | — | 0 programs |
| — |
VIVEbiotech
San Sebastián, Spain
|
Profiled | — | — | — | 0 programs |
| — |
Roche / Genentech (Internal Manufacturing & CustomBiotech)
Basel, Switzerland
|
Profiled | — | — | — | 0 programs |
| — |
Altruist Biologics
Suzhou, China
|
Profiled | — | — | Available | 0 programs |
| — |
Rose BioSolutions
Wilmington, MA
|
Profiled | — | — | — | 0 programs |
| — |
Orphan Therapeutics Accelerator (OTXL)
Cambridge, MA
|
Profiled | — | — | — | 0 programs |
| — |
Cellipont Bioservices
The Woodlands, TX
|
Profiled | — | — | — | 0 programs |
| — |
Coriolis Pharma
Martinsried (Munich), Germany
|
Profiled | — | — | — | 0 programs |
| — |
Porton Advanced
Cranbury, NJ
|
Profiled | — | — | — | 0 programs |
| — |
Kemwell Biopharma
Bengaluru, India
|
Profiled | — | — | — | 0 programs |
| — |
Vantage Vector (Demo)
Gaithersburg, MD
|
Profiled | — | — | Available | 0 programs |
| — |
Kemwell Biopharma, Bangalore
Bengaluru, India
|
Profiled | — | — | — | 0 programs |
| — |
Advanced BioScience Laboratories, Inc. (ABL Inc.)
Rockville, MD
|
Profiled | — | — | — | 0 programs |
| — |
Spur Therapeutics
London, United Kingdom
|
Profiled | — | — | — | 0 programs |
| — |
Ultragenyx (UX111 — AAV, Sanfilippo Syndrome Type A)
Novato, CA
|
Profiled | — | — | — | 0 programs |
| — |
AAV Gene Therapy Programs (Industry-Wide)
N/A — Industry Pattern
|
Profiled | — | — | — | 0 programs |
| — |
FUJIFILM Cellular Dynamics (FCDI)
Madison, WI
|
Profiled | — | — | — | 0 programs |
| — |
Eppendorf BioBLU
Hamburg, Germany
|
Profiled | — | — | — | 0 programs |
| — |
AAV Gene Therapy — Purification-Driven Program Failures (Industry Pattern)
N/A — Industry-Wide Pattern
|
Profiled | — | — | — | 0 programs |
| — |
Magellan Stem Cells
Sydney, Australia
|
Profiled | — | — | — | 0 programs |
| — |
Landmark Bio
Watertown, MA
|
Profiled | — | — | — | 0 programs |
| — |
Navigate BioPharma Services, Inc.
Carlsbad, CA
|
Profiled | — | — | — | 0 programs |
| — |
Cellistic
Mont-Saint-Guibert, Belgium
|
Profiled | — | — | — | 0 programs |
| — |
NegotiumBio LLC & GmbH
Basel, Switzerland (GmbH) / US entity (LLC)
|
Profiled | — | — | — | 0 programs |
| — |
IDT Biologika GmbH
Dessau-Roßlau, Germany
|
Profiled | — | — | — | 0 programs |
| — |
Pharmaron Biologics (Liverpool)
Liverpool, United Kingdom
|
Profiled | — | — | — | 0 programs |
| — |
Canton Biologics Co., Ltd.
Foshan (Shunde District), China
|
Profiled | — | — | — | 0 programs |
| — |
Canton Biologics
Guangzhou, China
|
Profiled | — | — | — | 0 programs |
| — |
Fresenius Kabi
Bad Homburg, Germany
|
Profiled | — | — | — | 0 programs |
| — |
InGeneron, Inc.
Houston, TX
|
Profiled | — | — | — | 0 programs |
| — |
Laurus Labs
Hyderabad, India
|
Profiled | — | — | — | 0 programs |
| — |
Genzyme (Sanofi)
Cambridge, MA (division of Sanofi, HQ: Paris, France)
|
Profiled | — | — | — | 0 programs |
| — |
Sanofi (Genzyme / Sanofi Manufacturing)
Paris, France
|
Profiled | — | — | — | 0 programs |
| — |
Novasep
Lyon, France
|
Profiled | — | — | — | 0 programs |
| — |
CDMO Industry — Market Size & Growth (2026)
Global
|
Profiled | — | — | — | 0 programs |
What to evaluate in a Cell & Gene Therapy CDMO
Integrated vs point-solution CDMO
Ex vivo cell therapy programs benefit from CDMOs handling both vector and cell processing under one roof. Point-solution CDMOs specialize deeper but add tech-transfer complexity.
Regulatory record by process class
Cell therapy and viral vector inspections are separately scoped. Verify the CDMO's inspection record on the specific process class your program will use.
Chain-of-identity + cold chain
Autologous cell therapy demands per-patient scheduling, batch-of-one tracking, and cold-chain logistics that CDMOs vary meaningfully on. Confirm the CDMO's chain-of-identity software and cryopreservation posture.
Commercial track record
For late-stage programs, CDMOs with commercial-approved cell or gene therapy products on file carry demonstrable posture that ranking algorithms only partially capture.
Which CDMOs integrate cell therapy processing with viral vector supply?
Integration matters most for ex vivo cell engineering — CAR-T and gene-modified HSC programs — where the vector and the cells need to move through a coordinated chain-of-identity. CDMOs covering both include Lonza (lentiviral + cell therapy at multiple sites), Catalent (AAV + cell therapy through the Paragon and MaSTherCell heritage), Charles River (multi-platform), and Thermo Fisher (viral vector + cell processing). The rankings above surface every CDMO tracked in either category; look for names appearing on both lentiviral and cell therapy filters as your integrated candidate shortlist.
How is cell therapy CDMO scoring different from vector CDMO scoring?
The Signal Score composition is identical, but the underlying signals diverge. Cell therapy CDMOs weight cleanroom infrastructure, chain-of-identity systems, cold-chain and cryopreservation posture, and per-patient batch process discipline. Vector CDMOs weight bioreactor scale, containment (BSL-2 for lentivirus), and analytics maturity. The Quality pillar reflects inspection history on the specific process class — a strong record on cell therapy inspections doesn't automatically de-risk vector manufacturing at the same site. Verify inspection scope at the profile level.
How CDMO Signal aggregates the cell and gene therapy view
This ranking is the union of CDMOs tagged with any viral-vector platform (AAV, lentiviral, adenoviral), any CDMO tagged directly with "gene therapy", and any CDMO tagged with "cell therapy". Each CDMO appears once regardless of how many categories they cover. This is the broadest advanced-therapy candidate list on our platform — for platform-specific filtering, use the dedicated modality pages.
What differentiates an approved-program cell and gene therapy CDMO?
CDMOs that have manufactured for approved cell or gene therapy products — Novartis/Kymriah (BMS Celgene), Gilead/Yescarta, bluebird bio's ex vivo gene therapies, Novartis Zolgensma — carry demonstrable commercial-scale posture. That level of track record is a hard buyer signal that no ranking algorithm captures perfectly; the Signal Score reflects it indirectly through inspection density and clinical footprint. For late-stage programs specifically, cross-reference the CDMO profile page with ClinicalTrials.gov and FDA product approvals for direct evidence.
Cell & Gene Therapy CDMOs — Frequently Asked Questions
Who are the top Cell & Gene Therapy CDMOs?
By CDMO Signal's independent Signal Score, the top-ranked Cell & Gene Therapy CDMOs include Bristol Myers Squibb (CGT Mfg), Novartis, City of Hope (T Cell Manufacturing). See the full ranked table above — scored on FDA, clinical, financial, and capacity data.
How many Cell & Gene Therapy CDMOs have FDA inspection records?
CDMO Signal tracks 31 Cell & Gene Therapy CDMOs with FDA inspection records and 323 EMA/MHRA GMP certificates across the group.
What should I look for in a cell and gene therapy CDMO?
Start with process class match — cell therapy vs vector vs both. For ex vivo programs benefit from integrated CDMOs. Verify inspection record on the specific process class, confirm capacity match to your patient volume, and prioritize CDMOs with commercial-scale posture for late-stage work.
How many cell and gene therapy CDMOs does CDMO Signal track?
109 CDMOs are tracked as cell or gene therapy manufacturers — the union of cell therapy, AAV, lentiviral, adenoviral, and gene therapy-tagged CDMOs. This is the broadest advanced-therapy candidate list on our platform.
Related modalities